Background: Sclerosis in the sacroiliac joints (SIJ) on radiography and computed tomography (CT) is common but widely considered a non-specific finding of sacroiliitis due to an association with degeneration and osteitis condensans ilii, despite little formal study. Availability of low dose radiation CT may lead to more widespread use for diagnostic evaluation. Objectives: We standardized the definition of sclerosis on CT and then aimed to determine whether this lesion could be reliably detected and its diagnostic utility. Methods: 215 CT scans were obtained from patients with a history of low back pain. 107 patients had a clinical diagnosis of spondyloarthritis (SpA) and 108 patients were clinically proven not to have SpA. Groups were age and gender matched (140 males, 75 females, mean age was 45 years). Three musculoskeletal radiologists, blinded to patient demographics and diagnosis, scored the CTs after standardization of lesion definitions and calibration. Erosions, sclerosis, and ankylosis were graded by size and number of articular surfaces/ joints involved. Sclerosis was considered definite if located along the cartilaginous compartment, measured >5mm in all 3 planes, and present >5mm from the joint surface. Discrepant scores were arbitrated and inter-reader reliability calculated by intra-class correlation coefficient (ICC). Diagnostic utility of CT lesions was determined by calculating sensitivity and specificity for the clinical diagnosis and by logistic regression. Results: ICC for sclerosis and erosion for each articular surface ranged from 0.65-0.76 and 0.71-0.78, respectively. ICC for ankylosis was 0.87-0.89. Sclerosis occurred in 87 (81%) cases with SpA and 25 (23%) controls. For a single articular surface the specificity for sacroiliitis ranged between 88-94%, for any two articular surfaces 95-100%, for all 4 articular surfaces 100%. Sensitivity ranged from 14% (4 articular surfaces) to 55% (either ilium). Erosion and ankylosis had a similar specificity range of 91-100% and 92-93%. The odds ratio was 4.9 for presence of definite sclerosis, and 12.6 for bilateral joint involvement. The odds ratio increased to 84.2 for bilateral erosion and 22.8 for bilateral ankylosis. Conclusions: When sclerosis measures >5mm in three planes and is located >5mm from a joint perimeter, it has high specificity for sacroiliitis, regardless of how many articular surfaces are involved, with similar specificity to erosion and ankylosis. Background: There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA) 1 was developed and validated. Identification of factors that predict long-term mMDA response in pSpA patients (pts) can facilitate decisions regarding treatment initiation and maintenance. Objectives: The purpose of this analysis was to determine predictors of long-term mMDA response following adalimumab (ADA) treatment in pSpA pts from the ABILITY-2 study. Methods: ABILITY-2 2 was a phase 3 randomized, double-blind trial evaluating the efficacy and safety of 40 mg ADA every other week versus placebo (PBO) over 12 weeks (wks) followed by open-label (OL) ADA for 144 wks in pts with pSpA. This post-hoc analysis included pts who received at least one dose of ADA during the PBO-controlled period or OL extension. The mMDA for pSpA was defined as achieving at least 5 out of the following 6 criteria: 1) TJC78 ≤1; 2) SJC76 ≤1; 3) pt pain visual analog scale (VAS) ≤15 of 100 mm; 4) pt global activity
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Conclusions:
Early mMDA response is a stronger and more consistent predictor of long-term mMDA, whether at 1, 2, or 3 yrs or sustained over time, than BL characteristics. The 5/6 versions of mMDA could be an appropriate treatment target in pSpA pts. Background: Low dose Computed Tomography (CT) could potentially be more sensitive than radiographs in the follow up of patients with axial spondyloarthritis (axSpA). Objectives: Our first goal was to develop a scoring method for the spine and test its interreader variability and frequency of progression in the various parts of the spine. Methods: Patients (pts) of the Sensitive Imaging of Axial Spondyloarthritis (SIAS) cohort fulfilled the modified New York (mNY) criteria, had ≥1 syndesmophyte in cervical or lumbar spine on radiographs and ≥1 inflammatory lesion on MRI-spine. Baseline and 2 years follow up low-dose CT scans (approximately 2-3 mSV) were performed. Syndesmophytes were scored in the coronal and sagittal planes for all "corners" per view, thus scoring 8 'quadrants' per vertebral unit (VU). Syndesmophytes were scored as absent (score 0), <50% of the intervertebral disc height (IVDH) (score 1), ≥50% of the IVDH but no bridging (score 2) or as "bridging the IDVH" (score 3). Score range 0-552. Two readers, blinded for clinical information and time order, scored the CT scans paired by patient. Scores of the 2 readers were compared using heatmaps. Interreader variability was assessed by (two-way average) ICC and smallest detectable change (SDC) for the whole spine and per segment. Results: In total, 56 pts (84% male, mean age 48.6) were included. The heatmap (fig 1) presents the similarity in basseline and change scores per reader per VU (VU on the y-axis). Ankylosis (score 3) is most prevalent in the thoracic spine, and syndesmophytes in general are least prevalent in the cervical spine. Both readers use almost the entire possible range, pick up a similar magnitude of change and have high ICCs. Most change is present in the thoracic spine. A change ≥SDC is seen in 33.9% of the patients. Conclusions: A fine-grained scoring system for CT spine was developed. Scoring syndesmophytes with good accuracy on CT images was feasible, picking up changes over a 2-year period in a high percentage of patients, especially in the thoracic spine, which is insufficiently visible on radiographs. ). However, although associations between fatigue, pain and PaGl have been examined to some extent on the group level, studies focusing on the agreement between these patient-reported measures in individual patients are missing. A better understanding of how tight the measures are bounded in individuals may improve our ability to deal with them in the daily clinic. Objectives: To examine associations on the group level and agreements on the individual patient level between fatigue, pain and PaGl as scored on visual analogue scales (VAS) in the daily clinic by patients with active spondyloarthropathy (SpA). Methods: Data on 118 SpA patients with active disease planned to initiate treatment with a biological agent were extracted from the Danish registry for biological treatment in rheumatology (DANBIO). Data included fatigue, pain and PaGl, BASDAI and BASFI assessed on VAS-scales (0-100) and age, CRP and physician global assessment. Associations between variables were examined using simple and multiple regression analysis (all mentioned variables including sex was incorporated as independent variables). Agreements between PaGl, pain and fatigue on the individual patient level was examined by Bland-Altman analyses yielding 95% lower and upper limits of agreement (LLoA and ULoA) between intra-individual assessments. The difference between the scores on the group level was expressed as the bias. 
